Harpoon Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash (used in) provided by operating activities
Stock-based compensation expense
Depreciation and amortization
Non-cash lease expense
Net amortization of discounts on marketable securities
Changes in operating assets and liabilities
Prepaid expenses and other assets
Other assets
Accounts payable
Accrued liabilities
Deferred revenue
Operating lease liabilities
Deferred revenue, non current
Other long-term liabilities

Net cash used in operating activities
Cash flows from investing activities
Purchases of property and equipment
Purchases of marketable securities
Maturities of marketable securities
Net cash (used in) provided by investing activities
Cash flows from financing activities
Proceeds from follow-on offering, net of issuance costs
Proceeds from issuance of common stock, net of issuance costs
Proceeds from issuance of convertible preferred stock, net of issuance costs
Proceeds from ATM, net of commissions and underwriting discounts
Proceeds from issuance of common stock in connection with employee benefit plans
Payments of deferred initial public offering costs
Series C Preferred Stock
Total payments of deferred initial public offering costs
Net cash provided by financing activities

Net increase (decrease) in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at beginning of period
Cash, cash equivalents, and restricted cash at end of period
Supplemental disclosures of non-cash investing and financing information
Conversion of preferred stock to common stock and additional paid-in capital
Deferred follow on offering costs included in accrued liabilities
Purchases of property and equipment included in accounts payable
Deferred initial public offering costs included in accounts payable and accrued liabilities
Reclassification of employee stock liability to equity upon vesting
Right-of-use asset obtained in exchange for lease obligation
Modification of operating lease
Tenant improvements provided by landlord
Series C preferred stock issuance costs included in accounts payable and accrued liabilities

Comments